pantoprazole has been researched along with Innate Inflammatory Response in 8 studies
Pantoprazole: 2-pyridinylmethylsulfinylbenzimidazole proton pump inhibitor that is used in the treatment of GASTROESOPHAGEAL REFLUX and PEPTIC ULCER.
pantoprazole : A member of the class of benzimidazoles that is 1H-benzimidazole substituted by a difluoromethoxy group at position 5 and a [(3,4-dimethoxypyridin-2-yl)methyl]sulfinyl group at position 2.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Pantoprazole can alleviate cancer cachexia-induced body weight reduction and inhibit skeletal muscle wasting in a dose-dependent manner." | 7.85 | Pantoprazole blocks the JAK2/STAT3 pathway to alleviate skeletal muscle wasting in cancer cachexia by inhibiting inflammatory response. ( Guo, D; Qiao, Z; Tang, H; Wang, C; Wang, Q, 2017) |
| "This study was embarked upon to evaluate the effects of pantoprazole and palonosetron on experimental esophagitis in albino wistar rats." | 7.83 | Effect of palonosetron (5HT-3 antagonist) and pantoprazole (proton pump inhibitor) against surgical esophagitis induced by forestomach and pylorus ligation in albino rats. ( Gautam, S; Kaithwas, G; Kumar, A; Rawat, JK; Saraf, SA; Singh, M, 2016) |
| "Pantoprazole can alleviate cancer cachexia-induced body weight reduction and inhibit skeletal muscle wasting in a dose-dependent manner." | 3.85 | Pantoprazole blocks the JAK2/STAT3 pathway to alleviate skeletal muscle wasting in cancer cachexia by inhibiting inflammatory response. ( Guo, D; Qiao, Z; Tang, H; Wang, C; Wang, Q, 2017) |
| "This study was embarked upon to evaluate the effects of pantoprazole and palonosetron on experimental esophagitis in albino wistar rats." | 3.83 | Effect of palonosetron (5HT-3 antagonist) and pantoprazole (proton pump inhibitor) against surgical esophagitis induced by forestomach and pylorus ligation in albino rats. ( Gautam, S; Kaithwas, G; Kumar, A; Rawat, JK; Saraf, SA; Singh, M, 2016) |
| "Since Omeprazole and pantoprazole decrease the secretion of TCTP which is associated with the development of allergic reaction, they may have the potential to serve as anti-allergic (asthmatic) drugs." | 3.75 | Proton pump inhibitors exert anti-allergic effects by reducing TCTP secretion. ( Choi, S; Hwang, ES; Kim, M; Lee, K; Min, HJ, 2009) |
| "Though long-term administration of proton pump inhibitor (PPI) imposed the risk of gastrointestinal track tumorigenesis by accompanied hypergastrinemia, no overt increases of colon cancer risk were witnessed after a long-term cohort study." | 1.40 | Paradoxically augmented anti-tumorigenic action of proton pump inhibitor and GastrininAPCMin/+ intestinal polyposis model. ( Hahm, KB; Han, YM; Hong, SP; Kim, EH; Park, JM, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (25.00) | 29.6817 |
| 2010's | 5 (62.50) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Ismail, RS | 1 |
| El-Awady, MS | 1 |
| Hassan, MH | 1 |
| Guo, D | 1 |
| Wang, C | 1 |
| Wang, Q | 1 |
| Qiao, Z | 1 |
| Tang, H | 1 |
| Han, YM | 1 |
| Hahm, KB | 1 |
| Park, JM | 1 |
| Hong, SP | 1 |
| Kim, EH | 1 |
| Kumar, A | 1 |
| Gautam, S | 1 |
| Rawat, JK | 1 |
| Singh, M | 1 |
| Saraf, SA | 1 |
| Kaithwas, G | 1 |
| Choi, S | 1 |
| Min, HJ | 1 |
| Kim, M | 1 |
| Hwang, ES | 1 |
| Lee, K | 1 |
| Gen, R | 1 |
| Demir, M | 1 |
| Ataseven, H | 1 |
| Shatzel, J | 1 |
| Wooten, K | 1 |
| Ankola, A | 1 |
| Cheney, RT | 1 |
| Morrison, CD | 1 |
| Skitzki, JJ | 1 |
| Becker, TL | 1 |
| Maróstica, M | 1 |
| Ribeiro, ML | 1 |
| de Mendonça, S | 1 |
| Gambero, A | 1 |
| Pedrazzoli, J | 1 |
8 other studies available for pantoprazole and Innate Inflammatory Response
| Article | Year |
|---|---|
Pantoprazole abrogated cisplatin-induced nephrotoxicity in mice via suppression of inflammation, apoptosis, and oxidative stress.
Topics: Animals; Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Caspase 3; Cisplatin; Cytokin | 2020 |
Pantoprazole blocks the JAK2/STAT3 pathway to alleviate skeletal muscle wasting in cancer cachexia by inhibiting inflammatory response.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenocarcinoma; Animals; Apoptosis; Cachexia; Cell Prolifer | 2017 |
Paradoxically augmented anti-tumorigenic action of proton pump inhibitor and GastrininAPCMin/+ intestinal polyposis model.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Active Transport, Cell Nucleus; Animals; Antineoplastic Age | 2014 |
Effect of palonosetron (5HT-3 antagonist) and pantoprazole (proton pump inhibitor) against surgical esophagitis induced by forestomach and pylorus ligation in albino rats.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Arachidonate 15-Lipoxygenase; Biomarkers; Cyclooxy | 2016 |
Proton pump inhibitors exert anti-allergic effects by reducing TCTP secretion.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Allergic Agents; Anti-Ulcer Agents; Biomarker | 2009 |
Effect of Helicobacter pylori eradication on insulin resistance, serum lipids and low-grade inflammation.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; C-Reactive Prote | 2010 |
Inflammatory myofibroblastic tumor of the mesentery: a clinical dilemma.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Inflammatory Agents; Celecoxib; Female; Humans; | 2012 |
Pantoprazole treatment does not invoke anti-inflammatory properties in vivo.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Inflammatory Agents; Anti-Ulcer Agents; Benzi | 2004 |